Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Aesthetic Plastic Surgery
Published in: Aesthetic Plastic Surgery 3/2021

01-06-2021 | Ptosis | Original Article

Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database

Authors: Salma Ahsanuddin, Savannah Roy, Wissam Nasser, Roman Povolotskiy, Boris Paskhover

Published in: Aesthetic Plastic Surgery | Issue 3/2021

Login to get access

Abstract

Background

Botulinum toxin treatment is the most frequently performed noninvasive cosmetic procedure performed in the USA. Because of its widespread use, an analysis of the adverse event (AE) profile of Botox injections is needed.

Methods

The FDA Adverse Event Report System was queried using an online web-based tool to determine the top 15 adverse events reported for four Botox brand names: Botox/Botox Cosmetic, Dysport, and Xeomin. The proportional reporting ratios (PRR) and relative odds ratios (ROR) were determined. A literature review was performed for eight AEs of clinical significance: eyelid/eyebrow ptosis, asthenia, muscular weakness, facial paresis, dysphagia, botulism, and death.

Results

Botox/Botox Cosmetic had 38367 AEs. Dysport had 3582 AEs. Xeomin had 1405 AEs. All drugs with reported cases of eyelid and eyebrow ptosis had significant PRR and ROR values. The PRR and ROR values for asthenia were not significant in any of the drugs and only reached significance for Dysport for muscular weakness and dysphagia. Both Botox/Botox Cosmetic and Dysport had elevated PRRs and RORs for facial paresis and botulism. While all drugs had at least one reported case of death related to Botox injection use, none of the PRR or ROR values were significant.

Conclusion

Known AEs for Botox injection use include eyelid/brow ptosis and muscular weakness. Feared but rare complications of Botox injection use include dysphagia, botulism, and possibly death, owing to systemic spread of the toxin. This is the first study to analyze the AE data reported to the FDA on Botox injection use.

EBM Level

III
Literature
1.
Surgeons, A.S.o.P.(2018) ASPS National clearinghouse of plastic surgery procedural statistics. p. 8.
2.
Dressler D, Saberi FA (2005) Botulinum toxin: mechanisms of action. Euro Neurol 53(1):3–9
3.
Guyuron B, Huddleston SW (1994) Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg 93(5):913–918PubMed
4.
Kao I, Drachman DB, Price DL (1976) Botulinum toxin: mechanism of presynaptic blockade. Science 193(4259):1256–1258PubMed
5.
Sobel J (2005) Botulism. Clin Infectious Dis 41(8):1167–1173
6.
Costa J et al. (2004) Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Syst Rev (2).
7.
Ward AB et al (2003) Use of botulinum toxin type A in management of adult spasticity-a European consensus statement. J Rehabilitation Med 35(2):98–99
8.
Ward A et al (2004) Community management and referral of spasticity following stroke. Medendi um Gro up Publishing, Berkhamsted, UK
9.
Molenaers G et al (2006) The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. JBJS 88(1):161–170
10.
Frampton JE, Easthope SE (2003) Botulinum Toxin A (Botox® Cosmetic). Am J Clin Dermatol 4(10):709–725.PubMed
11.
Mandavia R et al (2014) The use of botulinum toxin in otorhinolaryngology: an updated review. Clin Otolaryngol 39(4):203–209PubMed
12.
Jankovic J, Schwartz K (1990) Botulinum toxin injections for cervical dystonia. Neurology 40(2):277–277PubMed
13.
Brin MF et al. (2009) Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 61(6):961–70.e1–11.
14.
Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20(7):981–990PubMed
15.
Cavallini M et al (2014) Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg 40(5):525–536PubMed
16.
Coté TR et al (2005) Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53(3):407–415PubMed
17.
Ault A (2008) New Botulinum Toxin injection warnings issued postinjection symptoms include dysphagia, ptosis, and shortness of breath, according to the FDA. Skin Allergy News 39(3):13–13
18.
Dashtipour K, Pedouim F (2016) Botulinum Toxin: preparations for clinical use, immunogenicity, side effects, and safety profile. Semin Neurol 36(1):29–33PubMed
19.
Klein AW (2004) Contraindications and complications with the use of botulinum toxin. Clin Dermatol 22(1):66–75PubMed
20.
Yiannakopoulou E (2015) Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology 95(1–2):65–69PubMed
21.
Nong LB et al (2008) Severe respiratory failure after injection of botulinum toxin: case report and review of the literature. Zhonghua Jie He He Hu Xi Za Zhi 31(5):369–371PubMed
22.
Tugnoli V et al (2002) Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol 147(4):808–809PubMed
23.
24.
25.
Bate A, Edwards I (2006) Data mining in spontaneous reports. Basic Clin Pharmacol Toxicol 2006. 98(3):324–330.PubMed
26.
Almenoff JS et al (2006) Comparative performance of two quantitative safety signalling methods. Drug Saf 29(10):875–887PubMed
27.
Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Safety 10(6):483–486
28.
Sakaeda T et al (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796PubMedPubMedCentral
29.
30.
(EV-EWG), E.M.A.E.E.W.G. (2006)Guideline on the Use of statistical signal detection methods in the Eudravigilance data analysis system. Evaluation of medicines for human use, November 16.
31.
Bate A et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Euro J Clin Pharmacol 54(4):315–321
32.
Walker TJ, Dayan SH (2014) Comparison and overview of currently available neurotoxins. J Clin Aesthetic Dermatol 7(2):31
33.
Cox SE, Adigun CG (2011) Complications of injectable fillers and neurotoxins. Dermatol Ther 24(6):524–536.PubMed
34.
Filipo R et al (2012) Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope 122(2):266–270PubMed
35.
de Maio M, Bento RF (2007) Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis. Plast Reconstr Surg 20(4):917–927; discussion 928.
36.
Trindade de Almeida AR, Secco LC, Carruthers A (2011) Handling botulinum toxins: an updated literature review. Dermatol Surg 37(11):1553–1565PubMed
37.
Sundaram H et al (2016) Global aesthetics consensus: hyaluronic acid fillers and Botulinum Toxin Type A-recommendations for combined treatment and optimizing outcomes in diverse patient populations. Plast Reconstr Surg 137(5):1410–1423PubMedPubMedCentral
38.
Carruthers A, Carruthers J (2005) Botulinum toxin type A. J Am Acad Dermatol 53(2):284–290PubMed
39.
Sundaram H et al (2016) Aesthetic applications of botulinum toxin A in Asians: an international, multidisciplinary, Pan-Asian consensus. Plastic Reconstructive Surg Global Open 4(12).
40.
Ferrari A et al (2018) Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol 33(1):7PubMedPubMedCentral
41.
Simpson DM et al (2016) Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86(19):1818–1826PubMedPubMedCentral
42.
Aoki K et al (2005) Pharmacology of Botox, Dysport, Myobloc and BTX-A in animal models of efficacy and safety. In: Abstract presented at the international conference on basic and therapeutic aspects of Botulinum and Tetanus Toxins, Denver.
43.
Aoki KR (2002) Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40(7):923–928
44.
Ranoux D et al (2002) Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72(4):459–462PubMedPubMedCentral
45.
Adams G, Kirkness C, Lee J (1987) Botulinum toxin A induced protective ptosis. Eye 1(5):603–608PubMed
46.
Kirkness CM et al (1988) Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology 95(4):473–480PubMed
47.
Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. New England J Med 324(17):1186–1194
48.
Ellis MF, Daniell M (2001) An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Exp Ophthalmol 29(6):394–399PubMed
49.
Naik M et al (2008) Anterior chemodenervation of levator palpebrae superioris with botulinum toxin type-A (Botox®) to induce temporary ptosis for corneal protection. Eye 22(9):1132–1136PubMed
50.
Reddy UP, Woodward JA (2010) Abobotulinum toxin A (Dysport) and botulinum toxin type A (Botox) for purposeful induction of eyelid ptosis. Ophthal PlastReconstr Surg 26(6):489–491
51.
Ward SR, Minamoto VB, Suzuki KP, Hulst JB, Bremner SN, Lieber RL (2018) Recovery of rat muscle size but not function more than 1 year after a single botulinum toxin injection. Muscle Nerve 57(3):435–441PubMed
52.
Matharu MS BOTOX®(Botulinum toxin type A, BoNTA, Allergan) in the management of chronic migraine.
53.
Yaraskavitch M, Leonard T, Herzog W (2008) Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech 41(4):897–902PubMed
54.
Carruthers JA et al (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46(6):840–849PubMed
55.
Salles AG, Toledo PN, Ferreira MC (2009) Botulinum toxin injection in long-standing facial paralysis patients: improvement of facial symmetry observed up to 6 months. Aesthetic Plastic Surg 33(4):582–590
56.
Kim J (2013) Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol 34(2):319–324PubMed
57.
Mehdizadeh OB, Dielsn J, White MW (2016) Botulinum toxin in the treatment of facial paralysis. Facial Plastic Surg Clin 24(1):11–20.
58.
Roggenkämper P et al (1994) Orbicular synkinesis after facial paralysis: treatment with botulinum toxin. Doc Ophthalmol 86(4):395–402PubMed
59.
Omprakash H, Rajendran S (2008) Botulinum toxin deaths: What is the fact? J Cutaneous Aesthetic Surg 1(2):95
60.
Bhatia KP et al (1999) Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 67(1):90–93PubMedPubMedCentral
61.
Wilson F (2001) Botulinum toxin-A risks overcome by proper technique. Cosmetic Surg Times 12.
62.
63.
Zaninotto G et al (2004) The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. J Gastrointestinal Surg 8(8):997–1006
64.
Pasricha PJ et al (1994) Treatment of achalasia with intrasphincteric injection of botulinum toxin: a pilot trial. Ann Internal Med 121(8):590–591
65.
Mya NK et al (2019) Botox: the deadly beauty. Forensic Med Anat Res 7(1):13–17
66.
Li M, Goldberger BA, Hopkins C (2005) Fatal case of BOTOX®-related anaphylaxis? J Forensic Sci 50(1):JFS2004196-4.
67.
Rosenfield LK et al (2014) The first case report of a systemic allergy to onabotulinumtoxinA (Botox) in a healthy patient. Aesthetic Surg J 34(5):766–768
Metadata
Title
Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database
Authors
Salma Ahsanuddin
Savannah Roy
Wissam Nasser
Roman Povolotskiy
Boris Paskhover
Publication date
01-06-2021
Publisher
Springer US
Published in
Aesthetic Plastic Surgery / Issue 3/2021
Print ISSN: 0364-216X
Electronic ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-020-02027-z

Other articles of this Issue 3/2021

Aesthetic Plastic Surgery 3/2021 Go to the issue

Editor’s Invited Commentary

Invited Discussion on: The Dual Vascular Pedicle—A Novel Method to Approach Challenging Cases in Single-Staged Mastopexy Augmentation

Original Article

Trinity Lift: A Unique Technique for Endoscopic Midface and Lower Periorbital Unit Lift

Original Article

The Use of Semi-Absorbable Mesh and its Impact on Donor-Site Morbidity and Patient-Reported Outcomes in DIEP Flap Breast Reconstruction

Letter to the Editor

Comment on Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction With or Without Skin Reduction in Patients with Large Ptotic Breasts: A Case-Matched Analysis

Correction

Correction to: Airflow Considerations and the Effect of Webster’s Triangle in Reduction Rhinoplasty

Editor’s Invited Commentary

Invited Discussion on: Plane Change Versus Capsulotomy: A Comparison of Treatments for Capsular Contraction in Breast Augmentation Using the Subfascial Plane.